Therabene

Therabene is a biotechnology company focused on the development of novel therapeutics for the treatment of various cancers. The company's primary focus is on targeting Cripto-1 (CR-1), a cell surface protein that is highly expressed in many epithelial cancers but has limited expression in normal adult tissues. By leveraging its expertise in Cripto-1 biology, Therabene aims to develop targeted therapies, including monoclonal antibodies and small molecules, to inhibit tumor growth and metastasis. The company's lead programs are currently in the pre-clinical stage, targeting aggressive solid tumors such as breast and pancreatic cancer. Therabene's approach focuses on high-specificity targeting to minimize off-target effects and improve patient outcomes in refractory cancers.